Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Prices Public Offering at $51.75 per Share

The story has been updated to include the net proceed anount if underwriters exercise their over-allotment option in full.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher late on Tuesday priced its public offering of 17.5 million shares of its common stock at $51.75 per share.

Net proceeds from the offering are expected to be at least $877.4 million and will be used to pay a portion of its pending $6.8 billion acquisition of Beckman Coulter. Proceeds also may be used for general corporate purposes, if there are any remaining from the offering or if the Beckman deal fails to chttps://www.genomeweb.com/archive/danaher-buying-beclose.

Underwriters on the offering have been granted a 30-day option to purchase up to an additional 1.75 million shares. In a document filed with the US Securities and Exchange Commission, Danaher said that if the underwriters exercise their over-allotment option in full, net proceeds will total around $965.3 million.

Citi, Morgan Stanley & Co., Barclays Capital, and UBS Securities are joint book-running managers for the offering. Baird, Jefferies & Co., Banca IMI, Mitsubishi UFJ Securities, and Wells Fargo Securities are acting as co-managers.

The offering is expected to close on June 21.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.